HR+ BREAST CANCER
Clinical trials for HR+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+ BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug targets Gene-Amplified breast cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called SC-101 in 120 people with advanced breast cancer (triple-negative or hormone-receptor-positive) that has a specific gene change called NECTIN4 amplification. Participants receive the drug once a week through an IV. The goal is to see if the drug…
Matched conditions: HR+ BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin ConjuStar Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:32 UTC
-
CBD oil put to the test for breast cancer joint pain
Symptom relief Not yet recruitingThis phase 3 trial tests whether CBD oil can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for early breast cancer. About 130 participants will receive either CBD or a placebo for 12 weeks, then switch treatments. The study measures pain interference …
Matched conditions: HR+ BREAST CANCER
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC